Hormonal and temperature responses to the 5-HT1A receptor agonist flesinoxan in normal volunteers. 2002

William Pitchot, and Jacques Wauthy, and Michel Hansenne, and Emmanuel Pinto, and Sonia Fuchs, and Jean Reggers, and Jean-Jacques Legros, and Marc Ansseau
Psychiatric Unit, CHU Sart Tilman, 4000 Liège, Belgium. wpitchot@chu.ulg.ac.be

BACKGROUND Flesinoxan is a highly potent and selective 5-HT(1A) agonist and appears to be a potentially interesting neuroendocrine serotonergic probe. OBJECTIVE We assessed hormonal (ACTH, cortisol, prolactin and growth hormone) and temperature responses to flesinoxan in normal volunteers. METHODS In a double-blind placebo-controlled study, single doses of 0.5 mg and 1 mg were injected over 10 min into 12 healthy male volunteers at 1-week intervals. Temperature and hormonal responses were measured at times -30, 0, 15, 30, 60, 90, and 120 min. RESULTS Flesinoxan induced a significant and dose-dependent increase in adrenocorticotropic hormone (ACTH), cortisol, prolactin (PRL), growth hormone (GH) and a decrease in body temperature. Tolerance to flesinoxan was excellent. CONCLUSIONS These results showed the role of 5-HT(1A) mechanisms in the PRL, ACTH, cortisol, GH, and temperature responses to flesinoxan. In the present study, flesinoxan appears a very promising serotonergic neuroendocrine probe.

UI MeSH Term Description Entries
D008297 Male Males
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D010907 Pituitary Hormones Hormones secreted by the PITUITARY GLAND including those from the anterior lobe (adenohypophysis), the posterior lobe (neurohypophysis), and the ill-defined intermediate lobe. Structurally, they include small peptides, proteins, and glycoproteins. They are under the regulation of neural signals (NEUROTRANSMITTERS) or neuroendocrine signals (HYPOTHALAMIC HORMONES) from the hypothalamus as well as feedback from their targets such as ADRENAL CORTEX HORMONES; ANDROGENS; ESTROGENS. Hormones, Pituitary
D011985 Receptors, Serotonin Cell-surface proteins that bind SEROTONIN and trigger intracellular changes which influence the behavior of cells. Several types of serotonin receptors have been recognized which differ in their pharmacology, molecular biology, and mode of action. 5-HT Receptor,5-HT Receptors,5-Hydroxytryptamine Receptor,5-Hydroxytryptamine Receptors,Receptors, Tryptamine,Serotonin Receptor,Serotonin Receptors,Tryptamine Receptor,Tryptamine Receptors,Receptors, 5-HT,Receptors, 5-Hydroxytryptamine,5 HT Receptor,5 HT Receptors,5 Hydroxytryptamine Receptor,5 Hydroxytryptamine Receptors,Receptor, 5-HT,Receptor, 5-Hydroxytryptamine,Receptor, Serotonin,Receptor, Tryptamine,Receptors, 5 HT,Receptors, 5 Hydroxytryptamine
D001831 Body Temperature The measure of the level of heat of a human or animal. Organ Temperature,Body Temperatures,Organ Temperatures,Temperature, Body,Temperature, Organ,Temperatures, Body,Temperatures, Organ
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006854 Hydrocortisone The main glucocorticoid secreted by the ADRENAL CORTEX. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Cortef,Cortisol,Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11beta)-,11-Epicortisol,Cortifair,Cortril,Epicortisol,Hydrocortisone, (11 alpha)-Isomer,Hydrocortisone, (9 beta,10 alpha,11 alpha)-Isomer,11 Epicortisol
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D017366 Serotonin Receptor Agonists Endogenous compounds and drugs that bind to and activate SEROTONIN RECEPTORS. Many serotonin receptor agonists are used as ANTIDEPRESSANTS; ANXIOLYTICS; and in the treatment of MIGRAINE DISORDERS. 5-HT Agonists,5-Hydroxytryptamine Agonists,Serotonin Agonists,5-HT Agonist,5-Hydroxytrytamine Agonist,Receptor Agonists, Serotonin,Serotonergic Agonist,Serotonergic Agonists,Serotonin Agonist,Serotonin Receptor Agonist,5 HT Agonist,5 HT Agonists,5 Hydroxytryptamine Agonists,5 Hydroxytrytamine Agonist,Agonist, 5-HT,Agonist, 5-Hydroxytrytamine,Agonist, Serotonergic,Agonist, Serotonin,Agonist, Serotonin Receptor,Agonists, 5-HT,Agonists, 5-Hydroxytryptamine,Agonists, Serotonergic,Agonists, Serotonin,Agonists, Serotonin Receptor,Receptor Agonist, Serotonin

Related Publications

William Pitchot, and Jacques Wauthy, and Michel Hansenne, and Emmanuel Pinto, and Sonia Fuchs, and Jean Reggers, and Jean-Jacques Legros, and Marc Ansseau
May 1994, British journal of pharmacology,
William Pitchot, and Jacques Wauthy, and Michel Hansenne, and Emmanuel Pinto, and Sonia Fuchs, and Jean Reggers, and Jean-Jacques Legros, and Marc Ansseau
September 1996, Psychopharmacology,
William Pitchot, and Jacques Wauthy, and Michel Hansenne, and Emmanuel Pinto, and Sonia Fuchs, and Jean Reggers, and Jean-Jacques Legros, and Marc Ansseau
April 1994, The Journal of pharmacology and experimental therapeutics,
William Pitchot, and Jacques Wauthy, and Michel Hansenne, and Emmanuel Pinto, and Sonia Fuchs, and Jean Reggers, and Jean-Jacques Legros, and Marc Ansseau
August 1996, British journal of pharmacology,
William Pitchot, and Jacques Wauthy, and Michel Hansenne, and Emmanuel Pinto, and Sonia Fuchs, and Jean Reggers, and Jean-Jacques Legros, and Marc Ansseau
May 1997, European journal of pharmacology,
William Pitchot, and Jacques Wauthy, and Michel Hansenne, and Emmanuel Pinto, and Sonia Fuchs, and Jean Reggers, and Jean-Jacques Legros, and Marc Ansseau
August 1994, Pharmacology, biochemistry, and behavior,
William Pitchot, and Jacques Wauthy, and Michel Hansenne, and Emmanuel Pinto, and Sonia Fuchs, and Jean Reggers, and Jean-Jacques Legros, and Marc Ansseau
October 1999, Pharmacology, biochemistry, and behavior,
William Pitchot, and Jacques Wauthy, and Michel Hansenne, and Emmanuel Pinto, and Sonia Fuchs, and Jean Reggers, and Jean-Jacques Legros, and Marc Ansseau
April 1997, European journal of pharmacology,
William Pitchot, and Jacques Wauthy, and Michel Hansenne, and Emmanuel Pinto, and Sonia Fuchs, and Jean Reggers, and Jean-Jacques Legros, and Marc Ansseau
August 2006, Neuroscience letters,
William Pitchot, and Jacques Wauthy, and Michel Hansenne, and Emmanuel Pinto, and Sonia Fuchs, and Jean Reggers, and Jean-Jacques Legros, and Marc Ansseau
November 1989, Journal of cardiovascular pharmacology,
Copied contents to your clipboard!